Logo

Gilead and Galapagos NV Reports Filgotinib (JAK1i) achieve 1EP and 2EP in FINCH-2 P-III study for the Treatment of RA

Share this

Gilead and Galapagos NV Reports Filgotinib (JAK1i) achieve 1EP and 2EP in FINCH-2 P-III study for the Treatment of RA

Shots:

  • FINCH-2 trial assessing filgotinib administering qd (200/100mg) vs PBO in ratio (1:1:1) for 24 wks. in moderate-to-severe active RA patients- intolerant to bDMARDs
  • FINCH-2 results (N= ≥153): ACR20@12wk (66 vs 57.5 vs 31.1) & ACR20@24wk (69.4 vs 54.9 vs 34.5) whereas- ACR70@12wk (21.8 vs 14.4 vs 6.8)- ACR70@24wk (32.0 vs 20.3 vs 8.1) & DAS28LDA@12 (40.8 vs 37.3 vs 15.5)
  • Filgotinib was well tolerated in FINCH-2 trial with no new safety issues and occurrence of serious adverse events (4.1 %- 5.2 % 3.4 %) in patients
  • Gilead and Galapagos globally collaborated for filgotinib’s development and commercialization. Several trials are assessing filgotinib- including P-III FINCH 2 trial for RA/other inflammatory diseases- the EQUATOR P-II for PA- the TORTUGA study for AS- the DIVERSITY P-III trial for Crohn’s disease and the P-III SELECTION trial for ulcerative colitis

 Ref: Gilead | Image:Gilead


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions